SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs opportunities in sovereign AI and customized software, has helped fuel a rally to new highs. Bulls celebrate the momentum and potential AI growth, while bears argue the valuation is stretched and warn of a pullback.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising concerns about a future rival to established wireless carriers. Traders debate whether the threat could pressure T-Mobiles pricing and market share or whether the selloff overstates a challenge that would require substantial infrastructure and time to develop.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknets privacy and Bitcoin DeFi push is drawing attention, especially strkBTCs optional shielded Bitcoin transfers and the broader STRK20 privacy rollout; traders are also highlighting its STARK-based post-quantum security. The reaction is largely bullish on the technology and recent momentum, though some remain wary of token unlocks and persistent supply pressure.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for its Starlink Mobile ambitions has fueled a sharp selloff in AT&T shares. Traders debate whether it signals a meaningful long-term competitive threat or an overreaction, arguing that a competing network would take substantial time and investment; many are buying the dip and pointing to AT&Ts established business and dividend.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has fueled concerns that it could eventually compete with Verizon and other wireless carriers, weighing on VZ shares. Traders are split between seeing a meaningful long-term threat and calling the selloff overdone given the time, investment, and infrastructure needed to build a competing network; some are buying the dip for Verizons dividend.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Nasdaq-100 reentry and anticipated index-fund buying are drawing attention alongside optimism about a planned NIH effort to accelerate personalized cancer vaccines and the companys Merck-partnered melanoma-vaccine program. Bulls point to momentum and possible short-covering, while skeptics argue the rally has outrun fundamentals and the cancer-vaccine opportunity remains uncertain.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsomes steep share-price decline is prompting debate despite continued growth in Auvelity prescriptions. Traders are focused on whether the Alzheimers agitation launch is accelerating enough to meet expectations, while citing uncertainty about sales execution and managements limited updates; some attribute the weakness to broader biotech pressure, and buyout speculation remains unconfirmed.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas newly reported defense orders are drawing attention for expanding its autonomous-systems backlog and improving revenue visibility. Despite bullish reactions to the contract activity, traders are frustrated by continued share-price weakness and debate short pressure and dilution alongside whether the orders will translate into revenue and cash flow.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Attention centers on Himaxs upcoming quarterly results and whether revenue growth and margins can support its valuation, alongside longer-term hopes for CPO and automotive demand. Traders are split between buying the pullback and concerns about semiconductor weakness and rumored CPO competition.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleafs enhanced hostile bid for Aurora is driving discussion, with traders debating whether the stock-and-cash offer adequately values Aurora and whether Curaleaf should raise it or walk away. Auroras resistance and speculation about a rival suitor add uncertainty to the proposed acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million.
Vistagen Therapeutics (NASDAQ:VTGN) sharesread more...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million.
Vistagen Therapeutics (NASDAQ:VTGN) shares increased byread more...

After a Phase 3 Miss, Vistagen Drops New Data Bomb on Fasedienol

Vistagen (NASDAQ:VTGN) has given investors a potentially important new piece of the fasedienol puzzle, but one that needs to be viewed alongside a major setback earlier this year.

SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets. SRX said it […]

This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell

Equity

Vistagen’s Fasedienol did not show statistically significant improvements on primary and secondary endpoints. 

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of...

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2026...

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Companys clinical program for fasedienol nasal spray...

Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, June 1, 2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Vistagen Therapeutics Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.2361
Prev Close	$0.2462
Open	$0.2398
Dividend Yield	0.00%
50-Day Moving Average	$0.2596
Beta	1.48
Avg. Volume	29.67M
PE Ratio	-0.14

52-Week High	$5.14
52-Week Low	$0.198
Market Capitalization	$10.93M
EPS (Annual)	-$1.83
Price to Book	0.43
Revenue Per Employee	$30,951.22

Feed

News

Sentiment

Earnings

Fundamentals

Info

VTGN Fundamentals